Robert Z. Orlowski

@Myeloma_Doc · Houston, Texas · joined 06 Sep 2010

Deputy Chair of Lymphoma/Myeloma, Vice Chair MM Research @ MD Anderson; Translational researcher who hates myeloma. Tweets are my own. Retweets ≠ endorsements.

16 816Followers

5 530Following

42 666Posts total

5.9KViews on collected posts

Son gönderiler

Robert Z. Orlowski@Myeloma_Doc7 Sep

#Myeloma Paper of the Day: Study of prevalence and disability of Peripheral Neuropathy in pts w/ #Waldenström macroglobulinemia finds most frequently reported phenotype was sensory axonal demyelinating ranged from 8-37.5% in unselected cohorts: https://t.co/zQ7iSO5vS4. #wmsm http

629 views · 12 likes · 1 reposts · 0 replies Open on X →

Robert Z. Orlowski@Myeloma_Doc6 Sep

#Myeloma Paper of the Day: Systematic review & meta-analysis of diagnostic accuracy of fat pad & BM sampling for AL #amyloidosis finds fat pad & surgical/punch bx w/ similar sensitivity (0.80 & 0.77, respectively); one study w/ both yielded 0.89: https://t.co/q1E2yFsimg. #alsm ht

1.4K views · 27 likes · 6 reposts · 0 replies Open on X →

Robert Z. Orlowski@Myeloma_Doc5 Sep

#Myeloma Paper of the Day: A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in myeloma separates antigen loss from epitope loss, and works w/ ADCs, TCEs & CAR Ts: https://t.co/ixN7p0rajT. #mmsm https://t.co/RytQB9pAiy

1.8K views · 35 likes · 7 reposts · 0 replies Open on X →

Robert Z. Orlowski@Myeloma_Doc4 Sep

#Myeloma Paper of the Day: Study of efficacy & safety of bridging tx prior to CAR T in RRMM finds bispecific T-cell engager-based bridging, particularly talquetamab, achieved deepest responses & most effectively converted refractory dz B4 infusion: https://t.co/9FQAeYyIlH. #mmsm

2K views · 40 likes · 10 reposts · 2 replies Open on X →

Robert Z. Orlowski@Myeloma_Doc14 Mar 2022

Faculty positions available for #myeloma clinician scientists. Join our @MDAndersonNews #Myeloma Team! https://t.co/26SYW32VXE Please RT! https://t.co/9IxDriQVbF

0 views · 137 likes · 27 reposts · 22 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 4 gönderi, 10K–100K takipçi aralığıyla yan yana. kendi kitlesinin çok ötesine gösteriliyor ve kitle tepki veriyor.

Medyan görüntülenme1 623bu hesap92410K–100K için medyan

Erişim, %9.65%bu hesap3.62%10K–100K için medyan

Etkileşim, %2.31%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	1 623	924	1.76×
Erişim (görüntülenme ÷ takipçi)	9.65%	3.62%	2.67×
Etkileşim oranı	2.31%	1.52%	1.52×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2K4 Sep

1.8K5 Sep

1.4K6 Sep

6297 Sep

Last 4 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

2.58%4 Sep

2.31%5 Sep

2.31%6 Sep

2.07%7 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes69.1%114 in total

Reposts14.5%24 in total

Replies1.2%2 in total

Bookmarks15.2%25 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.